References

The impact of the COVID-19 pandemic on cancer care.

10.1038/s43018-020-0074-y · 2020 · External reference

Post-acute COVID-19 syndrome.

10.1038/s41591-021-01283-z · 2021 · External reference

Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies.

10.1016/j.ejca.2020.08.011 · 2020 · External reference

Factors associated with deaths due to COVID-19 versus other causes: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform.

10.1101/2021.01.15.21249756 · 2021 · External reference

Factors associated with COVID-19-related death using OpenSAFELY.

10.1038/s41586-020-2521-4 · 2020 · External reference

Predicting COVID-19 related death using the OpenSAFELY platform.

10.1101/2021.02.25.21252433 · 2021 · External reference

COVID-19 and cancer registries: learning from the first peak of the SARS-CoV-2 pandemic.

10.1038/s41416-021-01324-x · 2021 · External reference

SARS-CoV-2 and cancer: Are they really partners in crime?

10.1016/j.ctrv.2020.102068 · 2020 · External reference

COVID-19 and cancer comorbidity: Therapeutic opportunities and challenges.

10.7150/thno.51471 · 2021 · External reference

The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study.

10.1016/s1470-2045(20)30388-0 · 2020 · External reference

Mortality due to cancer treatment delay: systematic review and meta-analysis.

10.1136/bmj.m4087 · 2020 · External reference

COVID-19 and Cancer: a Comprehensive Review.

10.1007/s11912-020-00934-7 · 2020 · External reference

Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy.

10.1038/s41416-020-0948-x · 2020 · External reference

Case fatality rate of cancer patients with COVID-19 in a New York Hospital system.

10.1158/2159-8290.cd-20-0516 · 2020 · External reference

COVID-19 mortality in cancer patients: A report from a tertiary cancer centre in India.

10.7717/peerj.10599 · 2021 · External reference

Differences in mortality of cancer patients with COVID-19 in a Brazilian cancer center.

10.1053/j.seminoncol.2021.01.003 · 2021 · External reference

Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study.

10.1016/j.ejca.2021.03.035 · 2021 · External reference

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study.

10.1016/s0140-6736(20)31173-9 · 2020 · External reference

The mortality rate of COVID-19 was high in cancer patients: a retrospective single-center study.

10.1007/s10147-021-01863-6 · 2021 · External reference

Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy).

10.2217/fon-2020-0369 · 2020 · External reference

COVID-19 in breast cancer patients: A cohort at the Institut Curie hospitals in the Paris area.

10.1186/s13058-020-01293-8 · 2020 · External reference

Comparison of cancer patients to non-cancer patients among covid-19 inpatients at a national level.

10.3390/cancers13061436 · 2021 · External reference

Clinical characteristics and outcomes of cancer patients with COVID-19.

10.1002/jmv.25972 · 2020 · External reference

Characteristics and outcomes of coronavirus disease 2019 (COVID-19) patients with cancer: a single-center retrospective observational study in Tokyo, Japan.

10.1007/s10147-020-01837-0 · 2021 · External reference

Clinical characteristics, outcomes, and risk factors for mortality in hospitalized patients with COVID-19 and cancer history: a propensity score-matched study.

10.1186/s13027-020-00339-y · 2020 · External reference

Clinical risk factors for mortality in patients with cancer and COVID-19: a systematic review and meta-analysis of recent observational studies.

10.1080/14737140.2021.1837628 · 2021 · External reference

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

10.1016/s0140-6736(20)31187-9 · 2020 · External reference

Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak.

10.1158/2159-8290.cd-20-0422 · 2020 · External reference

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study.

10.1016/s1470-2045(20)30442-3 · 2020 · External reference

The immuno-oncological challenge of COVID-19.

10.1038/s43018-020-00122-3 · 2020 · External reference

Caring for patients with cancer in the COVID-19 era.

10.1038/s41591-020-0874-8 · 2020 · External reference

Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?

10.3389/fphys.2020.571416 · 2021 · External reference

Age-related mitochondrial dysfunction as a key factor in COVID-19 disease.

10.1016/j.exger.2020.111147 · 2020 · External reference

Cancer associates with risk and severe events of COVID-19: A systematic review and meta-analysis.

10.1002/ijc.33213 · 2021 · External reference

Statement - Catastrophic impact of COVID-19 on cancer care

2021 · External reference

Changes in the Number of US Patients With Newly Identified Cancer Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic.

10.1001/jamanetworkopen.2020.17267 · 2020 · External reference

Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study.

10.1016/s1470-2045(20)30392-2 · 2020 · External reference

Lockdown poses new challenges for cancer care in India.

10.1016/s1470-2045(20)30312-0 · 2020 · External reference

A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group.

10.1634/theoncologist.2020-0213 · 2020 · External reference

When cancer encounters COVID-19 in China: What have we suffered, experienced and learned.

10.1093/jjco/hyaa077 · 2020 · External reference

Challenges in lung cancer therapy during the COVID-19 pandemic.

10.1016/s2213-2600(20)30170-3 · 2020 · External reference

Impact of the COVID-19 Pandemic on Lung Cancer Screening Program and Subsequent Lung Cancer.

10.1016/j.jamcollsurg.2020.12.002 · 2021 · External reference

The Impact of COVID-19 Pandemic on Lung Cancer Community.

10.14740/wjon1367 · 2021 · External reference

Effect of age, comorbidity and remission status on outcome of COVID-19 in patients with hematological malignancies.

10.1016/j.bcmd.2020.102525 · 2021 · External reference

Hematological Abnormalities in COVID-19: A Narrative Review.

10.4269/ajtmh.20-1536 · 2021 · External reference

Treating Leukemia in the Time of COVID-19.

10.1159/000508199 · 2021 · External reference

COVID-19 in Older Individuals with Cancer: Problem and Potential Solutions.

10.1080/07357907.2020.1852567 · 2021 · External reference

Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study.

10.1016/j.ejca.2021.01.021 · 2021 · External reference

Management of patients with cancer during the COVID-19 pandemic: The Italian perspective on the second wave.

10.1016/j.ejca.2021.01.040 · 2021 · External reference

Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study.

10.1016/j.ejca.2021.02.027 · 2021 · External reference

Influence of clinical characteristics and anti-cancer therapy on outcomes from SARS-CoV-2 infection: A systematic review and meta-analysis of 5,678 cancer patients.

10.1101/2020.12.15.20248195 · 2020 · External reference

Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study.

10.1016/j.ejca.2020.09.027 · 2020 · External reference

Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology.

10.1200/go.20.00589 · 2021 · External reference

COVID-19 Consultation | BECA | Committees | European Parliament.

2021 · External reference

Immune-checkpoint inhibitors from cancer to COVID-19: A promising avenue for the treatment of patients with COVID-19 (Review).

10.3892/ijo.2020.5159 · 2021 · External reference

Repurposing anticancer drugs for the management of COVID-19.

10.1016/j.ejca.2020.09.014 · 2020 · External reference

Repurposing of anticancer drugs expands possibilities for antiviral and anti-inflammatory discovery in COVID-19.

10.1158/2159-8290.cd-21-0144 · 2021 · External reference

Abstract S02-01: Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI).

10.1158/1557-3265.covid-19-s02-01 · 2020 · External reference

COVID-19 and immune checkpoint inhibitors: Initial considerations.

10.1136/jitc-2020-000933 · 2020 · External reference

Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy.

10.1038/s43018-021-00191-y · 2021 · External reference

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

10.1016/s0140-6736(20)31187-9 · 2020 · External reference

Determinants of COVID-19 disease severity in patients with cancer.

10.1038/s41591-020-0979-0 · 2020 · External reference

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.

10.1136/jitc-2020-001931 · 2021 · External reference

SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19.

10.1016/j.ccell.2020.09.007 · 2020 · External reference

The impact of the SARS-CoV-2 infection, with special reference to the hematological setting.

10.1002/jmv.26197 · 2021 · External reference

Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies.

10.1016/j.it.2017.11.006 · 2018 · External reference

Artificial intelligence in COVID-19 drug repurposing.

10.1016/s2589-7500(20)30192-8 · 2020 · External reference

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.

10.1038/s41421-020-0153-3 · 2020 · External reference

Anakinra for severe forms of COVID-19: a cohort study.

10.1016/s2665-9913(20)30164-8 · 2020 · External reference

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.

10.1016/s0140-6736(21)00461-x · 2021 · External reference

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.

10.1056/nejmoa2031994 · 2021 · External reference

Efficacy and tolerability of bevacizumab in patients with severe Covid-19.

10.1038/s41467-021-21085-8 · 2021 · External reference

Management of patients with multiple myeloma during the COVID-19 pandemic.

10.1016/s2352-3026(20)30124-1 · 2020 · External reference

The Large Action of Chlorpromazine: Translational and Transdisciplinary Considerations in the Face of COVID-19.

10.3389/fphar.2020.577678 · 2020 · External reference

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.

10.1056/nejmoa2012410 · 2020 · External reference

Imatinib a Tyrosine Kinase Inhibitor: a potential treatment for SARS- COV-2 induced pneumonia.

10.1080/20905068.2020.1778417 · 2020 · External reference

Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19.

10.1001/jamaoncol.2020.2493 · 2020 · External reference

Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2.

10.1021/acs.jproteome.0c00397 · 2020 · External reference

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.

10.1126/science.abc6027 · 2020 · External reference

Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.

10.1111/bjh.16863 · 2020 · External reference

CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges.

10.1016/j.retram.2020.06.003 · 2020 · External reference

Low dose lung radiotherapy for COVID-19 pneumonia. The rationale for a cost-effective anti-inflammatory treatment.

10.1016/j.ctro.2020.04.006 · 2020 · External reference

Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors

10.2217/imt-2020-0067 · 2020 · External reference

Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes.

10.1186/s13054-020-03400-9 · 2020 · External reference

Risk factors and risk groups

2020 · External reference

Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic.

10.1002/pds.5029 · 2020 · External reference

CDC COVID Data Tracker

2020 · External reference

Coronavirus » Urgent cancer diagnostic services during COVID-19

2020 · External reference

Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan.

10.1001/jamaoncol.2021.2159 · 2021 · External reference